CellWell record HH-534692
The utility of eGFR difference (eGFRCystatin C - eGFRCreatinine) in the diagnosis, prognosis, and management of chronic kidney disease: a comprehensive review
Gerry George Mathew
2026
In plain language
This review reports that the difference between cystatin C- and creatinine-based eGFR is associated with reduced muscle mass, inflammation, and higher cardiovascular and mortality risk, improving risk prediction in chronic kidney disease.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-534692
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.